Watson Sues FDA on Generic Diabetes Drug Ruling

Generic drugmaker Watson Pharmaceuticals sued the U.S. Food and Drug Administration, challenging a ruling against Watson's generic version of a big-selling diabetes drug, Actos.

Watson said that the FDA improperly denied the company's shared exclusivity on the generic version despite Watson directly following directions received from the regulator.

As a result of the FDA's decision, approval could be delayed for up to six months, Watson said in a statement.

Watson planned to launch its generic version of Takeda Pharmaceutical's Actos on Aug. 17 after a 2010 settlement with the Japanese drugmaker.

The first company that files for approval of a generic version of an off-patent drug typically gets marketing exclusivity for 180 days.

An FDA spokeswoman said the agency would not comment on ongoing litigation.

Actos had total U.S. sales of about $2.7 billion for the twelve months ending May 31, Watson said, quoting IMS Health data.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.